Updates in Heart Failure 2024
Chairs: Gianluigi Savarese, Frieder Braunschweig
Organized by: Karolinska University Hospital
in collaboration with Translational medicine agency (TMA)
December 16th-17th 2024
DECEMBER 16th 2024 (DAY 1)
12.00-13.00
Lunch
13.00-13.05
- 13.00-13.05 | Greetings and introduction to the congress
Gianluigi Savarese (SE), Frieder Braunschweig (SE)
Session 1: Implementation of GDMT: time to act (joint session with the Heart Failure Association of the European Society of Cardiology)
Chairpersons: Ovidiu Chioncel (RO), Marco Metra (IT), Antoni Bayés-Genis (ES), Maurizio Volterrani (IT)
13.05-14.45
- 13.05-13.15 | The secret recipe for starting the 4 pillars
Alexandre Mebazaa (FR) - 13.15-13.25 | How are we doing with ARNi and SGLT2i?
Davide Stolfo (SE) - 13.25-13.35 | Breaking down barriers – the point of view of the nephrologist on worsening renal function during GDMT
Per-Henrik Groo (FN) - 13.35-13.45 | hyperkalemia – are we reaching a consensus for its management?
Gianluigi Savarese (SE) - 13.45-13.55 | Why do we talk about implementation?
Felix Lindberg (SE) - 13.55-14.05 | What strategies to implement use of GDMT?
Gianluigi Savarese (SE) - 14.05-14.15 | How to effectively handle decongestion in daily clinical practice
Wilfried Mullens (BE) - 14.15-14.45 | Round Table: Ask the experts
All
14.45-15-00
Coffee Break
Session 2: Post-MI heart failure
Chairpersons: Mark Petrie (UK), Lars H. Lund (SE), Antonio Cannata (UK)
15.00-16.10
- 15.00-15.10 | The sizes of the problem
Giulia Ferrannini (SE) - 15.10-15.20 | The DAPA-MI: drawing conclusions
Stefan James (SE) - 15.20-15.30 | The EMPACT-MI: the last piece of the puzzle?
Javed Butler (US) - 15.30-15.40 | How do we reconcile data on the treatment of post-MI HF
Antoni Bayes-Genis (SP) - 15.40-16.10 | Round Table: Ask the experts
All
16.10-16.25
Coffee Break
Session 3: Iron deficiency in HF: have we gained enough evidence?
Chairpersons: Frieder Braunschweig (SE), Gianluigi Savarese (SE), Ovidiu Chioncel (RO)
16.25-17.15
- 16.25-16.35 | Iron deficiency in HF: a summary of evidence until 2023
Giuseppe Rosano (UK)
- 16.35-16.45 | FAIR-HF2: the last piece of evidence
Stefan D. Anker (GR)
- 16.45-16.55 | How do we reconcile evidence and future perspectives
John Cleland (UK)
- 16.55-17.15 | Round Table: Ask the experts
All
- 17.15-17.40 | Lecture 1: New advances in the field of cardioncology
Chair: Agneta Månsson Broberg (SE), Speaker: Markus Anker (GR)
- 17.40-18.05 | Lecture 2: Hypertension and HFpEF
Chair: Gianluigi Savarese (SE), Speaker: Anasthasios J. Manolis (GR)
- 18.05-18.10 | Closure of the day
Frieder Braunschweig (SE), Gianluigi Savarese (SE)
December 17th 2024 (day 2)
- 08.25-08.30 | Greetings
Savarese G (SE), Frieder Braunschweig (SE)
- 08.30-08.55 | Lecture 3: Management of HFpEF: the world beyond SGLT2i
Chair: Gianluigi Savarese (SE), Speaker: Lars H. Lund (SE)
Session 4: GLP1Ra – a new pillar in HF pharmacotherapy?
08.55-09.55
Chairpersons: Giuseppe Rosano (UK), Stefan D. Anker (DE), Antoni Bayés-Genis (ES)
- 08.55-09.05 | Obesity: a therapeutic target in patients with HF?
Biykem Bozkurt (US) - 09.05-09.15 | GLP1Ra in HF: the available evidence
Mark Petrie (UK) - 09.15-09:25 | What is coming next?
Javed Butler (US) - 09.25-09:50 | Round Table: Ask the experts
All
- 09.50-10.15 | Lecture 4: Increasing patient adherence in patients with HF
Chair: Michael Böhm (GR), Speaker: Giuseppe Rosano (UK)
Coffee Break
10.15-10.30
Session 5: Heart Failure Devices
Chairpersons: John Cleland (UK), Wilfried Mullens(BE), Marcus Stålberg (SE)
10.30-11.30
- 10.30-10.40 | Primary prophylactic ICD in HF: towards precision medicine
Frieder Braunschweig (SE) - 10.40-10.50 | CRT: when is OMT and time to proceed with implantation?
Cecilia Linde (SE) - 10.50-11.00 | Monitoring devices
Michael Melin (SE) - 11.00-11.30 | Round Table: Ask the experts
All
Session 6: Treating mitral and tricuspid regurgitation in HF
11.30-12.40
Chairpersons: Finn Gustafsson (DK), Giuseppe Rosano (UK), Egidio Imbalzano (IT), Bahira Shahim (SE)
- 11.30-11.40 | Updates in the treatment of TR
Marco Metra (IT) - 11.40-11.50 | Where do we stand for the treatment of fMR?
Andreas Rück (SE) - 11.50-12.00 | Treating aortic stenosis in HFrEF: when is it too late or too early?
Marianna Adamo (IT) - 12.00-12.10 | Lessons learnt from previous trials on TEER: how to design the next?
Javed Butler (US) - 12.10-12.40 | Round Table: Ask the experts
All
12.40-13.40
Lunch
- 13.40-14.05 | Lecture 5: Atrial fibrillation in HF: drugs or interventions?
Chair: Frieder Braunschweig (SE), Speaker: John Cleland (UK)
- 14.05-14.30 | Lecture 6: Advanced heart failure: state-of-the art and future perspectives
Chair: Michael Melin (SE), Speaker: Finn Gustafsson (DE)
14.30-14.45
Coffee Break
Session 7: Non only heart failure… cardiomyopathies!
14.45-16.00
Chairpersons: Ovidiu Chioncel (RO), Egidio Imbalzano (IT), Maurizio Volterrani (IT)
- 14.45-14.55 | Cardiac amyloidosis: current and future treatments
Davide Stolfo (SE) - 14.55-15.05 | Hypertrophic cardiomyopathy: current and future treatments
Antonio Cannata (UK) - 15.05-15.15 | Laminopathies: current treatment and future perspectives
Kristina Haugga (NR) - 15.15-16.00 | Round Table: Ask the experts
All
Session 8: The best of HF publications in 2024
16.00-16.30
Chairpersons: Marco Metra (IT), Camilla Hage (SE)
- 16.00-16.10 | ESC Journals
Michael Böhm (GR) - 16.10-16.20 | JACC Journals
Biykem Bozkurt (US) - 16.20-16.30 | Circ Journals
Gabriele Schiattarella (GR)
- 16.40-16.55 | Lecture 7: What to expect in 2025 (15 min presentation)
Chair: Gianluigi Savarese (SE), Speaker: Lars H. Lund (SE)
- 16.55-17.00 | Closure of the day
Gianluigi Savarese (SE), Frieder Braunschweig (SE)